|Bid||163.46 x 800|
|Ask||163.94 x 800|
|Day's Range||162.96 - 164.06|
|52 Week Range||133.65 - 179.92|
|Beta (5Y Monthly)||0.70|
|PE Ratio (TTM)||28.92|
|Earnings Date||Oct 19, 2021|
|Forward Dividend & Yield||4.24 (2.56%)|
|Ex-Dividend Date||Aug 23, 2021|
|1y Target Est||188.29|
In this article, we discuss the 11 best dividend stocks to buy according to Warren Buffett. You can skip our detailed analysis of Buffett’s hedge fund and his investment philosophy and go directly to read the 5 Best Dividend Stocks To Buy According To Warren Buffett. Warren Buffett is an American businessman, investor, and CEO […]
AstraZeneca (NASDAQ: AZN) awaits U.S. Emergency Use Authorization for its COVID-19 antibody therapy as a prophylaxis. In this Motley Fool Live video recorded on Oct. 13, Motley Fool contributors Keith Speights and Brian Orelli discuss how effective AstraZeneca might be in competing against antibody therapies marketed by COVID-19 antibody therapies already on the market.
In this Motley Fool Live video recorded on Oct. 13, Fool contributors Keith Speights and Brian Orelli discuss two upcoming U.S. Food and Drug Administration (FDA) approval decisions that investors should keep an eye on. Keith Speights: Brian, on another note, the FDA is set to make several important approval decisions in the fourth quarter. Brian Orelli: Biomarin (NASDAQ: BMRN) has one coming up on Nov. 20.